These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18021517)

  • 21. Management of alveolar hemorrhage in lung vasculitides.
    Casian A; Jayne D
    Semin Respir Crit Care Med; 2011 Jun; 32(3):335-45. PubMed ID: 21674419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ANCA-associated vasculitis].
    Sinico RA; Sabadini E; Boeri R; Radice A
    G Ital Nefrol; 2002; 19(2):125-36. PubMed ID: 12195410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical review: Vasculitis on the intensive care unit -- part 2: treatment and prognosis.
    Semple D; Keogh J; Forni L; Venn R
    Crit Care; 2005 Apr; 9(2):193-7. PubMed ID: 15774077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic study of intractable vasculitis].
    Abe T
    Nihon Rinsho; 1994 Aug; 52(8):2169-72. PubMed ID: 7933606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical practice guideline for ANCA-associated vasculitis with renal involvement].
    Vazquez V; Fayad A; González G; Smuclir Quevedo A; Robaina Sindín J;
    Medicina (B Aires); 2015; 75 Suppl 1():1-38. PubMed ID: 26738202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Microscopic polyangiitis].
    Venetz JP; Rossert J
    Ann Med Interne (Paris); 2000 May; 151(3):193-8. PubMed ID: 10896971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.
    Harper L; Savage CO
    Rheumatology (Oxford); 2005 Apr; 44(4):495-501. PubMed ID: 15613403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis.
    Sinico RA; Di Toma L; Radice A
    Autoimmun Rev; 2013 Feb; 12(4):477-82. PubMed ID: 22921791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary systemic vasculitis.
    Day C; Savage C
    Minerva Med; 2001 Oct; 92(5):349-63. PubMed ID: 11675579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and therapy in systemic vasculitis with renal involvement].
    Andrassy K; Ritz E
    Ther Umsch; 1994 Dec; 51(12):813-8. PubMed ID: 7784994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.
    Kronbichler A; Jayne DR; Mayer G
    Eur J Clin Invest; 2015 Mar; 45(3):346-68. PubMed ID: 25627555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of therapy for ANCA-associated vasculitis.
    Turnbull J; Harper L
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):391-401. PubMed ID: 19508946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ANCA-associated vasculitis: diagnosis, clinical characteristics and treatment.
    Haubitz M
    Vasa; 2007 May; 36(2):81-9. PubMed ID: 17708098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement.
    Rihova Z; Jancova E; Merta M; Rysava R; Reiterova J; Zabka J; Tesar V
    Kidney Blood Press Res; 2005; 28(3):144-52. PubMed ID: 15908752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.